implications for treating patients with icosapent ethyl
Published 4 years ago • 2.2K plays • Length 4:25Download video MP4
Download video MP3
Similar videos
-
3:03
considerations for treating with icosapent ethyl
-
5:22
robert busch, md: reduce-it trial implications, icosapent ethyl for diabetes patients
-
3:40
expert commentary: icosapent ethyl lowers cardiovascular risk in people with diabetes | jay shubrook
-
2:34
fda committee says vascepa can be given to larger population of patients
-
7:15
cost-effectiveness data and pricing of icosapent ethyl
-
5:28
high triglycerides? try this omega 3 bomb
-
12:02
how i reversed 20 years of arterial plaque
-
4:47
organophosphate poisoning: what you need to know to stay safe!
-
2:21
vascepa approved to reduce cardiovascular risk
-
7:50
high triglycerides (part 1) - medication vs. lifestyle - eicosapent ethyl
-
13:32
vascepa the "super fish oil" - is it for you?
-
4:38
the reduce-it study and cv risk
-
7:39
thoughts on anticardiolipin antibodies for assessing blood clotting issues and inflammation
-
0:52
the pill burden in hyperphosphatemia
-
4:17
esc 23: liberate-hefh: novel pcsk9-inhibitor in heterozygous familial hypercholesterolemia
-
1:54
do you need to eat healthy and exercise while taking cholesterol medications?
-
2:35
targeting triglycerides to reduce cv risk
-
2:57
dr. matthew budoff discusses final evaporate results
-
28:11
associations between lipoprotein (a), hypertension, and cardiovascular disease
-
3:41
cost-effectiveness of pcsk9 inhibitors for heterozygous fh or ascvd
-
4:49
'phenomenal' reduce-it establishes triglyceride theory
-
5:33
is there a price to pay for increased patency in peripheral arteries with paclitaxel-coated devices?